**Authors:** Ayanda Trevor Mnguni<sup>1,2</sup>, Denzil Schietekat<sup>2</sup>, Nabilah Ebrahim<sup>2</sup>, Nawhaal Sonday<sup>2</sup>, Nicholas Boliter<sup>2</sup>, Neshaad Schrueder<sup>1</sup>, Shiraaz Gabriels<sup>1</sup>, Annibale Cois<sup>3,5</sup>, Jacques L. Tamuzi<sup>3</sup>, Yamanya Tembo<sup>5</sup>, Mary-Ann Davies<sup>4,5</sup>, Rene English<sup>3</sup>, Peter S. Nyasulu<sup>3,6\*</sup> for the COVID-19 Research Response Collaboration.

## Affiliations

<sup>1</sup>Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

<sup>2</sup>Khayelitsha District Hospital, Cape Town, South Africa

<sup>3</sup>Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

<sup>4</sup>Health Impact Assessment Directorate, Western Cape Government, Cape Town, South Africa

<sup>5</sup>School of Public Health and Family Medicine, University of Cape Town, South Africa <sup>6</sup>Division of Epidemiology & Biostatistics, School of Public Health, Faculty of Medicine and Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

\*Corresponding authors: Peter S Nyasulu <pnyasulu@sun.ac.za> and Ayanda Trevor Mnguni <trevormnguni@sun.ac.za>

#### 4 Abstract

Background: COVID-19 experiences on noncommunicable diseases (NCDs) from
 district-level hospital settings during waves I and II are scarcely documented. The aim of
 this study is to investigate the NCDs associated with COVID-19 severity and mortality in
 a district-level hospital with a high HIV/TB burden.

9

**Methods:** This was a retrospective observational study that compared COVID-19 waves 10 I and II at Khayelitsha District Hospital in Cape Town, South Africa. COVID-19 adult 11 patients with a confirmed SARS-CoV-2 polymerase chain reaction (PCR) or positive 12 antigen test were included. In order to compare the inter wave period, clinical and 13 laboratory parameters on hospital admission of noncommunicable diseases, the Student 14 t-test or Mann-Whitney U for continuous data and the X2 test or Fishers' Exact test for 15 categorical data were used. The role of the NCD subpopulation on COVID-19 mortality 16 was determined using latent class analysis (LCA). 17

Findings: Among 560 patients admitted with COVID-19, patients admitted during wave 18 II were significantly older than those admitted during wave I. The most prevalent 19 comorbidity patterns were hypertension (87%), diabetes mellitus (65%), HIV/AIDS (30%), 20 obesity (19%), Chronic Kidney Disease (CKD) (13%), Congestive Cardiac Failure (CCF) 21 22 (8.8%), Chronic Obstructive Pulmonary Disease (COPD) (3%), cerebrovascular accidents (CVA)/stroke (3%), with similar prevalence in both waves except HIV status 23 [(23% vs 34% waves II and I, respectively), p = 0.022], obesity [(52% vs 2.5%, waves II)24 25 and I, respectively), p < 0.001], previous stroke [(1% vs 4.1%, waves II and I, respectively), p = 0.046]. In terms of clinical and laboratory findings, our study found that wave I patients 26

had higher haemoglobin and HIV viral loads. Wave II, on the other hand, had statistically 27 significant higher chest radiography abnormalities, fraction of inspired oxygen (FiO2), and 28 uraemia. The adjusted odds ratio for death vs discharge between waves I and II was 29 similar (0.94, 95%CI: 0.84-1.05). Wave I had a longer average survival time (8.0 vs 6.1 30 days) and a shorter average length of stay among patients discharged alive (9.2 vs 10.7) 31 days). LCA revealed that the cardiovascular phenotype had the highest mortality, followed 32 by diabetes and CKD phenotypes. Only Diabetes and hypertension phenotypes had the 33 lowest mortality. 34

**Conclusion:** Even though clinical and laboratory characteristics differed significantly between the two waves, mortality remained constant. According to LCA, the cardiovascular, diabetes, and CKD phenotypes had the highest death probability.

38

Keywords: COVID-19, noncommunicable diseases, mortality, HIV, TB, district hospital,
 South Africa

## 42 Introduction

The Coronavirus disease 2019 (COVID-19) pandemic continues to accelerate with South 43 Africa at the time of writing experiencing its 4<sup>th</sup> wave of COVID-19 infections. As of 29<sup>th</sup> 44 October 2022, official statistics report 4,027,157 cumulative confirmed cases of COVID-45 19, including 102,311 reported deaths in South Africa [1]. South Africa is a middle-income 46 country with coinciding epidemics of non-communicable diseases (NCDs) and chronic 47 infectious diseases including a high prevalence of human immunodeficiency virus (HIV) 48 and tuberculosis (TB). Demographic and Health Survey found that 41% of adult women 49 and 11% of men were obese, 46% of women and 44% of men were hypertensive, and 50 13% of women and 8% of men had diabetes [2], and estimated overall HIV prevalence is 51 52 13,7% [3] with 852 cases (95% CI 679–1026) per 100 000 population of TB [4]. Evidence suggests that COVID-19 patients with NCDs and chronic infectious diseases such as 53 54 diabetes, hypertension, cardiovascular disease, chronic kidney diseases (CKD), HIV, and TB are at an increased risk of disease severity and mortality [5-7]. The most common 55 comorbidities reported in high HIV/TB burden settings among patients with severe 56 COVID-19 are hypertension, heart failure, diabetes, cancer in the previous 5 years, 57 chronic pulmonary disease, obesity, CKD, HIV and TB [7-10]. While high-income 58 countries have vaccinated many of their populations, low-middle income countries lag 59 due to a combination of factors such as vaccine inequity, slow vaccine rollout programs 60 due to poor administration, and vaccine hesitancy. These comorbidities are still an urgent 61 threat to COVID-19 severity and mortality in high HIV/TB and under-resourced health 62 settings such as district hospitals. The Beta variant was identified as the primary cause 63 of the rapid increase in infections during Wave II in South Africa [11, 12]. The increased 64

disease severity, the ability to escape previously acquired immunity as evidenced by 65 increased hospitalizations and case fatality rate were attributed to the various mutations 66 in the Beta variant when compared to its predecessors such as the Alpha variant and the 67 original wild-type Wuhan strain [12-14], and the ability to escape previously acquired 68 immunity [12, 15]. This contributed to the severity and mortality of COVID-19 in wave II. 69 70 District level hospital experiences provide a unique opportunity to study the effects of the pandemic at the 'grassroots' level, which informs the success or failure of public health 71 interventions. According to a review of the literature, there is no study describing the 72 effects of NCDs on COVID-19 outcomes at a high burden HIV/TB district level hospital 73 setting. The aim of this study is to investigate the comorbidities that are linked to COVID-74 19 severity and mortality between waves I and II. 75

76 Methods

#### 77 Study Design

This was a retrospective observational study on the epidemiological and clinical
 characteristics of COVID-19 at Khayelitsha District Hospital, Cape Town, South Africa
 from March 2020 – January 2021.

81 Study Population

We included all consecutive patients, 18 years and older with COVID-19 as confirmed by a positive antigen test or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase polymerase chain reaction (RT-PCR) result requiring hospital admission from March 2020 until January 2021. The main indication for hospitalization was COVID-19 pneumonia requiring oxygen therapy. Patients were followed up until

completed hospital course (either discharge, transfer to tertiary or field hospital or death).

88 Patients with incomplete outcome data were excluded.

89 Setting

South Africa has a dual health system that includes a publicly funded district health 90 system that serves approximately 84% of the population nationally and a private health 91 system that is primarily funded by private health insurance schemes [16]. The district level 92 healthcare system, along with the primary healthcare system, are the primary points of 93 contact for COVID-19 patients and oversee providing healthcare to the vast majority of 94 South Africans. Khayelitsha District Hospital is a 330-bed hospital in Mandela Park, 95 Khayelitsha that opened in 2012. Khayelitsha is a township in South Africa, south-east of 96 Cape Town (Figure 1). Most of the people (98.6%) are black Africans [17]. It was 97 constructed during the Apartheid era to enforce the Group Areas Act. Khayelitsha was 98 intended to be isolated, situated on dune land with a high risk of seasonal flooding, and 99 entirely residential, with no designated commercial or industrial zones [18]. Most of the 100 population (55.6%) live in informal housing. Khayelitsha has South Africa's highest 101 concentration of poverty and unemployment rate. Furthermore, Khayelitsha has the worst 102 health indicators in Cape Town, with the highest rates of mortality for stroke, 103 hypertension, and diabetes mellitus [19, 20]. 104

**Data Collection** 

We collected baseline, the demographic, clinical, laboratory and outcome data on hospital
 admission, from digital registries, with additional data were captured from electronic
 medical records.

The baseline and clinical data collected included demographic information such as age and sex, symptoms on admission to hospital, presence of comorbidities including, hypertension, diabetes, overweight or obesity [defined as a body mass index (BMI) $\geq$ 25 or  $\geq$ 30 kg/m2 respectively or as documented by treating clinicians as the BMI was not captured for all patients, cardiac disease, chronic kidney disease, and active or previous history of TB.

Baseline arterial blood gas and laboratory values including severity indices were also captured. These included the partial pressure of arterial oxygen to fraction of inspired oxygen (P/F Ratio), the white cell count (WCC), the neutrophil to lymphocyte ratio (N/L ratio), serum creatine (Cr), glycated haemoglobin (HbA1c) and the C-Reactive protein (CRP), hemo glucose test (HGT), uremia, CD4 count, and viral load were captured if they were done up to a year prior to admission. The main outcome of the study was in-hospital death or survival to discharge.

123 Stati

### Statistical Methods

Data were imported into R Statistical Software v. 4.0.5 (R Core Team, Vienna, Austria) for pre-processing and analysis. Sample characteristics were described as mean and standard deviation (SE) or median and interquartile ranges (IQR) for continuous variables, and frequency for categorical measures. Student t test and or Mann–Whitney

U test were used to investigate differences in the distribution of continuous variables between sub-groups of patients. X<sup>2</sup> test or Fishers' Exact test were used to investigate differences in the distribution of categorical variables. Latent Class Analysis (LCA) was used to identify latent subpopulations with similar NCD patterns [21]. The Aalen-Johansen method was used to assess the competing risks of in-hospital mortality and discharge [22].

Uncertainty in the estimates was quantified by reporting their 95% confidence intervals
(CI) or standard error (SE). To define statistical significance, a p-value of 0.05 was used
as a cut-off. To deal with missing data, a pairwise deletion method was used.

**Ethical approval** 

Ethical approval for the study was obtained from the Stellenbosch University health research ethics committee (Ethics reference number: N20/05/020\_COVID-19).

140

### 141 **Results**

### **Sample Characteristics**

A total of 580 patients with SARS-CoV-2 infection were admitted to the hospital during the study period. From those, we excluded the 19 cases with missing triage and/or outcome (death/discharge) date, and a case with missing age at admission. Of the remaining 560, 367 patients were admitted during the first wave of the pandemic (April-July 2020 in South Africa), and 193 during the second (November 2020 – January 2021). 148 The distribution of admissions by triage date is shown in Figure 2. Demographic, lifestyle,

and clinical characteristics of the sample are summarised in Table1, separately by wave.

150

Table 1: Demographic, lifestyle, and clinical characteristics of the sample

151

			Wave		
Variable	Ν	Overall, N =	Wave I, N =	Wave II, N =	p-value
		560	367	193	(1)
Gender	560				0.2
Female		374 (67%)	238 (65%)	136 (70%)	
Male		186 (33%)	129 (35%)	57 (30%)	
Age	560	58 (50, 66)	57 (50, 66)	59 (51, 68)	0.092
Age class	560				0.032
14-39		34 (6.1%)	29 (7.9%)	5 (2.6%)	
40-59		273 (49%)	179 (49%)	94 (49%)	
60-79		228 (41%)	140 (38%)	88 (46%)	
>80		25 (4.5%)	19 (5.2%)	6 (3.1%)	
Current smoking	560	17 (3.0%)	9 (2.5%)	8 (4.1%)	0.3
Current drug use	560	1 (0.2%)	0 (0%)	1 (0.5%)	0.3
Current alcohol use	560	14 (2.5%)	5 (1.4%)	9 (4.7%)	0.023
HIV/AIDS	428	130 (30%)	96 (34%)	34 (23%)	0.022
Current/Previous TB	560	24 (4.3%)	15 (4.1%)	9 (4.7%)	0.7
Hypertension	560	485 (87%)	318 (87%)	167 (87%)	>0.9
Diabetes	560	362 (65%)	232 (63%)	130 (67%)	0.3
Obesity	560	109 (19%)	9 (2.5%)	100 (52%)	<0.001
Dyslipidemia	560	12 (2.1%)	6 (1.6%)	6 (3.1%)	0.4
CKD	560	75 (13%)	47 (13%)	28 (15%)	0.6
Asthma	560	10 (1.8%)	8 (2.2%)	2 (1.0%)	0.5
COPD	560	17 (3.0%)	9 (2.5%)	8 (4.1%)	0.3
CCF	560	49 (8.8%)	26 (7.1%)	23 (12%)	0.054
IHD	560	10 (1.8%)	9 (2.5%)	1 (0.5%)	0.2
Mitral Valve Disease	560	6 (1.1%)	4 (1.1%)	2 (1.0%)	>0.9
Stroke	560	17 (3.0%)	15 (4.1%)	2 (1.0%)	0.046
Cancers	560	6 (1.1%)	4 (1.1%)	2 (1.0%)	>0.9
Psychiatric disorders	560	15 (2.7%)	11 (3.0%)	4 (2.1%)	0.5
Epilepsy	560	8 (1.4%)	7 (1.9%)	1 (0.5%)	0.3
Other comorbidities	560	66 (12%)	28 (7.6%)	38 (20%)	<0.001

n (%)

(1) Pearson's Chi-squared test; Fisher's exact test

152

153 Abbreviations: CKD: chronic kidney disease, CCF: congestive cardiac failure, COPD: Chronic Obstructive Pulmonary

154 Disease, HIV/AIDS: human immunodeficiency virus/ acquired immune deficiency syndrome, IHD: Ischaemic Heart

155 Disease, TB: tuberculosis

Patients admitted during wave II were significantly older than those admitted during wave I (2.6% vs 7.9% of subjects under 40, 45% vs 38% of subjects aged 60-69 years), and were 3 times more likely to be current drinkers. The comorbidity patterns were overall similar, with the notable exception of higher prevalence of HIV positive status (34% vs 23%) and previous stroke (4.1% vs 1.0%) in wave I. In contrast, a higher prevalence of obesity was observed in wave II (52% vs 2.5%).

The most frequent presenting complaint was shortness of breath (71% of patients across the two waves), cough (69%), fever (37%), myalgia (21%), sore throat (14%) and chest pain (11%). Shortness of breath and myalgia were significantly more frequent in wave II, and chest pain more common in wave I (Table A3: Additional Material).

Table 2 summarises the data collected at triage and the results of the laboratory tests. 167 Subjects in wave II had more frequently CXR abnormalities (55% vs 10%, p<0.001), 168 higher median (IQR) temperature [36.80(36.10 - 37.10) vs 36.60(36.30 - 37.20), p = 169 (0.014)] and FiO<sub>2</sub> [21(21-21) vs 21(21-80), p<0.001)] and lower systolic and diastolic BP 170 [124 (117, 151) vs 133(108, 137), p<0.001] and [76(68-83) vs 80(71-90), p<0.001] and 171 pulse rate [97(88, 107) vs 102(88-114), p = 0.004]. Laboratory results differed with higher 172 mean uraemia in wave II [8(5, 13) vs 7(4-12), p = 0.033]. In contrast the median (IQR) 173 haemoglobin and HIV viral load were higher in wave I [13.30(12.00 - 14.30) vs 12.70(11.50 174 175 -13.90), p = 0.003] and [(20(20-28) vs 20(20-20), p = 0.045)], respectively.

176 177

		Wave	
Variable	N	Overall, N = Wave I, N = 367	Wave II, N = p-value
		560	193 (1)

Table 2: Triage data and laboratory results

CXR	560	145 (26%)	38 (10%)	107 (55%) •	<0.001
abnormality					
Respiratory	545	20 (18, 28)	20 (18, 28)	20 (19, 26)	0.4
Rate					
Pulse rate	549	100 (88, 112)	102 (88, 114)	97 (88, 107)	0.004
Systolic BP	547	129 (113, 148)	133 (117, 151)	124 (108, 137) •	<0.001
Diastolic BP	547	79 (70, 87)	80 (71, 90)	76 (68, 83) •	<0.001
Hypertension	547	208 (38%)	160 (44%)	48 (26%) •	<0.001
Temperature	529	36.70 (36.20,	36.60 (36.10,	36.80 (36.30,	0.014
		37.10)	37.10)	37.20)	
SPO2	549	92 (85, 96)	92 (85, 96)	92 (84, 96)	0.7
PaO2	310	7.70 (6.10,	7.50 (6.10, 9.20)	7.70 (6.30,	0.5
		9.50)		10.30)	
FiO2	210	21 (21, 40)	21 (21, 21)	21 (21, 80) •	<0.001
HGT	492	12 (7, 20)	12 (7, 21)	12 (8, 17)	0.4
Uremia	553	7 (5, 13)	7 (4, 12)	8 (5, 13)	0.033
Creatinine	553	93 (69, 145)	94 (69, 143)	93 (73, 158)	0.5
C-reactive	491	148 (76, 229)	146 (71, 231)	154 (94, 224)	0.3
protein					
WCC	552	9.2 (6.9, 11.8)	9.2 (6.8, 12.1)	9.4 (7.1, 11.5)	0.8
Haemoglobin	551	13.10 (11.80,	13.30 (12.00,	12.70 (11.50,	0.003
		14.15)	14.30)	13.90)	
PLTS	551	281 (220, 367)	280 (215, 364)	282 (225, 368)	0.7
Lymphocytes	435	1.64 (1.25,	1.63 (1.19,	1.65 (1.29,	0.2
		2.14)	2.08)	2.16)	
Neutrophils	434	6.7 (4.7, 8.9)	6.6 (4.5, 9.0)	6.8 (5.0, 8.6)	0.8
CD4	101	336 (212, 480)	306 (228, 460)	410 (147, 558)	0.4
Viral Load	90	20 (20, 23)	20 (20, 28)	20 (20, 20)	0.045

Median (IQR)

(1) Wilcoxon rank sum test

Abbreviations: BP; blood pressure, CD4: cluster of differentiation 4, HGT: Hemo Glucose Test, PLTS: Platelets, SpO2: Oxygen saturation, PaO2: Partial Pressure of Oxygen, FiO2: fraction of inspired oxygen, WCC: White Cell Count

## 178 Interventions and complications

- 179 Table 3 shows the frequency of various interventions in the two waves, while Table 4
- 180 summarises the reported complications.

181

## Table 3: Interventions

			Wave		
Variable	N	Overall, N =	Wave I, N =	Wave II, N =	p-value
		560	367	193	(1)
Co-trimoxazole	560	6 (1.1%)	3 (0.8%)	3 (1.6%)	0.4
O <sub>2</sub>	560	425 (76%)	263 (72%)	162 (84%)	0.001
Corticosteroids	281	220 (78%)	53 (51%)	167 (94%)	<0.001
Ceftriaxone	560	93 (17%)	40 (11%)	53 (27%)	<0.001
Azithromycin	560	73 (13%)	35 (9.5%)	38 (20%)	<0.001
Amoxicillin +	560	13 (2.3%)	6 (1.6%)	7 (3.6%)	0.15
Clavulanic Acid					
Unspecified antibiotic	560	323 (58%)	278 (76%)	45 (23%)	<0.001
n (%)					
(1) Pearson's Chi-squ	ared te	st; Fisher's exa	ct test		
	Tab	le 4: Reported co	omplications		

187

184

185

186

			Wave		
Variable	Ν	Overall, N =	Wave I, N =	Wave II, N =	p-value
		560	367	193	(1)
AKI	560	126 (22%)	69 (19%)	57 (30%)	0.004
Shock	560	10 (1.8%)	10 (2.7%)	0 (0%)	0.018
ARDS	560	45 (8.0%)	5 (1.4%)	40 (21%)	<0.001
HAP	560	6 (1.1%)	4 (1.1%)	2 (1.0%)	>0.9
DIC	560	2 (0.4%)	2 (0.5%)	0 (0%)	0.5

n (%)

<sup>(1)</sup> Pearson's Chi-squared test; Fisher's exact test

Abbreviations: AKI: Acute kidney injury, ARDS: Acute respiratory distress syndrome, DIC: Disseminated intravascular coagulation, HAP: Hospital-acquired pneumonia

188

## 189 Interventions and complications

- 190 Table 3 shows the frequency of various interventions in the two waves, while Table 4
- 191 summarises the reported complications.

Most subjects had O<sub>2</sub> and corticosteroids administered during their hospital stay, and in 192 both cases, the frequency of the intervention was significantly higher in wave II. The 193 between-waves comparison of the type of antibiotics administered was partly hindered by 194 the substantial number of cases where the type is unspecified. Overall, data suggests 195 significantly higher use of oxygen (72% vs 84%, P<0.001), corticosteroids (51% vs 94%, 196 p<0.001), ceftriaxone (11% vs 27%, p<0.001), Azithromycin (9.5% vs 20%, p<0.001) in 197 the second wave compared to the first. Acute Kidney Injury (19% vs 30%, p = 0.004) and 198 ARDS (1.4% vs 21%, p<0.001) were more common complications in wave II, while shock 199 (2.7% vs 0%, p = 0.018) was predominant in wave I. 200

#### 201 Outcomes

The proportion of subjects dead as a function of the number of days after triage is shown in Figure 3. The figure indicates a slightly higher risk of mortality in wave II, consistent over time. However, the differences were not statistically significant, and disappeared completely after adjustment for age and comorbidities at baseline. The odds ratio for death vs discharge between wave I and wave II were 1.3 (95% CI: 0.76-2.19) in the unadjusted analyses, and 0.94 (0.84-1.05) after adjustment.

The average survival time was 8 days in wave I (ranging from 0 to 58 days) and 6.1 days in wave II (1 to 25 days). The average length of stay of patients discharged alive was 9.2 days in wave I (ranging from 0 to 89 days) and 10.7 days in wave II (0 to 68 days).

NCD patterns

Latent class analysis suggests the presence in the population of 4 latent classes (see 213 Additional Material for modelling details). The comorbidity patterns observed in each class 214 are shown in Figure 4. Phenotype 1 ('Cardiovascular') is characterised by high prevalence 215 of cardiovascular diagnoses (IHD, mitral valve disease, CCF, stroke, accompanied by 216 significant prevalence of diabetes and CKD). Phenotype 2 ('CKD') is characterised by the 217 highest prevalence of diabetes and CKD, but minimal prevalence of other diseases 218 (excluding hypertension, which is highly prevalent across the four phenotypes). 219 220 Phenotype 3 ('*Diabetes*') shows high prevalence of diabetes but no CKD and the lowest prevalence of obesity. Phenotype 4 ('Hypertension'), finally, shares with the remaining 221 222 groups a high prevalence of hypertension but has a relatively 'healthy' comorbidity profile regarding the other disease considered. Tables A2, A3 and A4 in Additional Material 223 224 summarise the characteristics of the four phenotypes in terms of presenting complaints, 225 triage variables and laboratory results, respectively.

Figure 5 shows the probability of deaths by time from triage, separately by latent phenotypes. It clearly indicated that individuals with phenotype 1 and 2 (Cardiovascular and CKD) have the highest risk of death at any point in time. Phenotype 3 and 4 (diabetes and hypertension) have the best probability of survival. The risk of death is similar for the two groups in the first two weeks from triage. Afterwards, phenotype "diabetes" had a slightly better prognosis.

232

233

234 **Discussion** 

This retrospective cohort study of 560 patients focused on the interactions between 235 SARS-CoV-2 infection and NCDs during two COVID-19 waves in a district level hospital 236 in South Africa. The median (IQR) age was 58 (50-66) years and females (67%) were 237 more prevalent than males (33%). The cohort included patients with hypertension (87%), 238 diabetes (65%) and obesity (30%). A third of the cohort was HIV infected. The target 239 240 organ damage associated with NCDs included CKD (13%), CCF (8.8%) and cerebrovascular accidents (3%). In comparison to wave II, wave I had a statistically 241 significant higher proportion of patients with HIV/AIDS and stroke. In contrast, wave II had 242 a statistically significant higher proportion of old age, current alcohol use, dyslipidemia, 243 and CCF and obesity. The higher proportion of obesity in wave II should be interpreted 244 with caution because there was little emphasis on capturing BMI in the first wave as 245 obesity was not recognized as a marker of disease severity. Obesity/increased BMI was 246 found to be associated with poor outcomes as the pandemic evolved. In terms of clinical 247 and laboratory findings, our study found that wave I had a statistically significant higher 248 pulse rate, systolic BP, diastolic BP, hypertension, haemoglobin, and HIV viral load. 249 However, wave II had statistically significant higher CXR abnormalities, temperature, 250 251 FiO2, and uremia. In the latent class, our study found that cardiovascular disease, diabetes mellitus, and CKD had a higher mortality rate after triage than diabetes without 252 CKD and hypertension. In wave I, the average survival time was 8.0 days, and in wave 253 254 II, it was 6.1 days. Our findings were consistent with previous research that found shorter survival times in wave II [8, 11]. Lalla et al. demonstrated that the probability of intensive 255 care unit (ICU) survival was higher during the second wave than the first [12]. This could 256 257 be explained by evidence-based and effective available interventions such as High-flow

nasal oxygen (HFNO) and steroids in the ICU setting. The average length of stay for
discharged alive patients was 9.2 days in wave I and 10.7 days in wave II. The data
showed a slightly higher risk of mortality in wave II, but the difference was not statistically
significant.

HIV was independently associated with increased COVID-19 mortality in a large cohort 262 263 study conducted in the Western Cape [6]. Furthermore, people with HIV who had a history of unsuppressed viral load were more likely to die in a hospital than suppressed HIV 264 patients [11]. Tenofovir disoproxil fumarate (TDF), which is used in the first-line 265 antiretroviral therapy (ART) regimen in South Africa, has been linked to new or worsening 266 renal failure [11, 23], and other antiretroviral drugs have been linked to hyperlipidaemia, 267 cardiac disease, and diabetes [11, 24]. The presence of comorbidities among PLWH was 268 linked to an increased risk of COVID-19 mortality [11]. Thus, HIV may play a significant 269 role in the emergence of NCDs in high-burden settings like the one studied here. 270 Additionally, higher HIV rates in wave I may be associated with non-communicable 271 diseases, increasing the mortality rate in wave I as the adjusted odds ratio for death vs 272 discharge between wave I and wave was 0.94. (0.84-1.05). In comparison to a large 273 274 cohort that stated that current/previous TB were predictors of COVID-19 in-hospital mortality, the small number of current/previous TB cases (24/560, 4.3%) had no effect on 275 the study findings [6, 7]. 276

In our study, latent class analysis revealed that stroke was included in the cardiovascular
(4.1%), CKD (3.7%), hypertension (3.5%), and diabetes mellitus (2.1%) phenotypes.
Psychiatric disorders were also prevalent in the hypertension phenotype (1.8%). The
presence of comorbidities was associated increased with severity of COVID-19 infection

(Honardoost et al., 2020). Cerebrovascular disease had the strongest association, 281 followed by cardiovascular diseases (CVDs), chronic lung disease, diabetes, and 282 hypertension [25]. Even though hypertension is associated with an up to 2.5-fold 283 increased risk of severe or fatal COVID 19, particularly in older individuals (Lippi et al., 284 2020) compared to other comorbidities such as COPD (over 5-fold higher risk) [26, 27] 285 and CKD (over 3-fold higher risk), it still has important clinical implications [27]. 286 Hypertension is also associated with a pro-inflammatory state, as evidenced by increased 287 levels of Angiotensin II, chemokines, cytokines, Interleukin-6 (IL-6) and tumour necrosis 288 factor (TNF) [28]. According to one study, the risks of adverse heart failure outcomes 289 increased significantly in patients with high systolic blood pressure, but this trend was 290 less obvious in patients with high diastolic blood pressure [29]. Our findings were also 291 consistent with a study that found high blood pressure to be a significant predictor of an 292 unfavourable COVID-19 prognosis [29]. High SBP/DBP variability, on the other hand, was 293 associated with a high risk of mortality, implying that maintaining stable in-hospital BP in 294 COVID-19 patients is critical [29]. 295

As previously discussed, evidence suggests that patients with noncommunicable 296 297 diseases such as diabetes, hypertension, cardiovascular disease, and chronic kidney disease have increased Angiotensin-Converting Enzyme 2 (ACE2) receptor expression, 298 which facilitates SARS-CoV-2 entry in the host and thus increases disease severity and 299 mortality [5]. Obesity, metabolic complications, and COVID-19 severity were all linked, 300 with a focus on fat mass distribution and insulin resistance [30]. This is well established 301 in our latent analysis, where CCF (100%), diabetes mellitus (67.3%), CKD (40.8%), IHD 302 (12.2%), and dyslipidaemia (6.1%) contributed to the highest cardiovascular phenotype 303

mortality rate. Similarly, the phenotypes diabetes mellitus and CKD had a high mortality 304 rate. Diabetic patients have an increased risk of COVID-19 due to increased expression 305 of a type one protease called Furin [31]. Furin facilitates the attachment of the SARS-306 CoV-2 spike protein to the ACE-2 receptor in diabetic patients, which is associated with 307 a dysregulated host immune response with increased ACE2 receptors and Furin levels, 308 which may be associated with lower insulin levels and worsening inflammation [31]. 309 Similarly, low-grade systemic inflammation associated with obesity is associated with 310 poor outcomes in COVID-19 patients [32]. This low-grade inflammation is linked to a 311 hyperimmune inflammatory state known as the cytokine storm [33]. The cytokine storm 312 that occurs during SARS-CoV-2 infection may also contribute to the high prevalence of 313 anaemia found in our study. Haemoglobin levels decreased with age, as did the 314 percentage of subjects with diabetes, hypertension, and other comorbidities [34]. 315

In this study, we also found that COVID-19 patients in wave II were older, had a higher 316 rate of abnormal CXR, dyslipidemia, CCF, and FIO2. Increasing age, underlying 317 cardiovascular diseases, and lower PaO2/FiO2 ratio values comprised the Brixia score; 318 when this score was higher, it was a significant predictor of COVID-19 death [35]. Brixia 319 320 score on initial CXR predicts fatal outcome in COVID-19 patients (based on in-hospital and out-of-hospital deaths) [35]. The higher proportion of CXR abnormality in wave II may 321 be due to more disease severity than in wave I. This is supported by Figure 3, which 322 compares mortality between waves I and II. This also is consistent with studies that found 323 a new strain of the virus caused more severe infections, as evidenced by abnormal CXR 324 [36-39]. This cohort included patients with moderate to severe COVID-19, with 76% being 325 oxygen dependent and 78% receiving corticosteroid therapy. The cohort had a 326

PaO2/FiO2 ratio of 276mmHg, which is consistent with mild acute respiratory distress
 syndrome, and 22% of the cohort had acute kidney injury.

329 A meta-analysis revealed that AKI was a common and serious complication of COVID-19 [40]. AKI was associated with older age and having severe COVID-19 [40]. In patients 330 with COVID-19 complicated by AKI, the risk of dying in the hospital was significantly 331 332 increased [40, 41]. According to one study, nearly half of COVID-19 patients with ARDS had AKI during their hospital stay [41]. This could explain the high rate of AKI and ARDS 333 complications during wave II, indicating that the Beta variant was associated with 334 increased severity and cytokine storm [12]. Currently, the mechanism of AKI in COVID-335 19 patients is thought to involve SARS-CoV-2 directly attacking intrinsic renal cells [40]. 336 High ACE2 expression in proximal tubular epithelial cells could be a target for kidney 337 damage. As previously described, high-load SARS-CoV-2 infection causes a cytokine 338 storm in which various inflammatory mediators are released, resulting in ischaemia, 339 hypoxia, fibrosis, and kidney damage [42-47]. Furthermore, COVID-19 that is 340 accompanied by high temperature, shock, dehydration, and hypoxemia, and is managed 341 with antibiotics and other potentially nephrotoxic drugs which may cause AKI [44]. 342 343 Increased age, diabetes mellitus, and hypertension were also found to cause or worsen the occurrence and progression of AKI in our study. This is consistent with other studies 344 that show an association between AKI and the parameters [28, 48]. AKI and increasing 345 age are also plausible explanations for the uricemia observed in wave II. In addition, 346 Moledina et al. found that AKI in COVID-19 may be caused by a combination of some 347 typical AKI risk factors, such as hypotension and volume depletion [47]. AKI could also 348 cause hypotension, volume depletion, and shock, as seen in wave I, where shock was 349

predominant. However, viral septic shock is frequently overlooked in clinical diagnosis;
 studies have shown that COVID-19 patients developed sepsis, leading to subsequent
 multiple organ dysfunction [34, 44, 49]. We hypothesize that the high rate of shock
 described in wave I could be hypovolemic and or sepsis related.

Despite emerging evidence that treatment with empirical administration of antibiotics such 354 355 as azithromycin and ceftriaxone does not reduce the risk of death in hospitalized COVID-19 patients [50], our study found that antibiotics were used more frequently in wave II 356 than in wave I in the district hospital. This could be attributed to the severity of illness 357 associated with wave II, the level of clinical experience of clinicians in the district hospital 358 (often juniors) combined with the delay in turnaround time in obtaining a positive 359 COVID19 result in patients with a syndrome of a pneumonia requiring oxygen. Clinicians 360 in this setting felt more comfortable in commencing empiric antibiotics. A meta-analysis 361 of 18 RCTs enrolling 2826 patients found that higher use of corticosteroids may reduce 362 mortality in patients with ARDS [51]. Patients who received a longer course of 363 corticosteroids lived longer than those who received a shorter course [51]. The landmark 364 RECOVERY trial found that there was a 28-day mortality reduction in patients 365 hospitalized with COVID-19 who received corticosteroid therapy [52]. However, in 366 patients who are immunocompromised such as HIV, diabetes mellitus, CKD, and Obesity 367 which is associated with low grade inflammation, high doses and a prolonged course of 368 corticosteroids render COVID-19 patients susceptible to active and latent TB [53]. This 369 could also lead to hypoinflammation and delayed viral clearance, resulting in increased 370 SARS-CoV-2 viral shedding in the lungs and kidneys, explaining ARDS and AKI in wave 371 II. The use of high-flow oxygen through a nasal cannula significantly reduced the need 372

for mechanical ventilation support and the time to clinical recovery in patients with severe COVID-19 when compared to conventional low-flow oxygen therapy [54]. It is worth noting that patients admitted with severe COVID-pneumonia were not given mechanical ventilation or high flow nasal oxygen at the district hospital setting due to limited human and infrastructure resources.

378 To the best of our knowledge, this is the first relatively large retrospective cohort that provides precise information about the characteristics of noncommunicable disease in 379 waves I and II in terms of demographics, clinical characteristics, triage data and laboratory 380 results, interventions, and complications patterns, including a latent analysis in a high 381 HIV/TB district hospital. This study used data from routine clinical practice; thus, data 382 could be incomplete or incorrect, leading to potential misclassification. To mitigate the 383 impact of incompleteness, we have selectively reported database-specific outcomes. 384 Patients who required mechanical ventilation or high flow nasal oxygen were transferred 385 to our referral centre due to limited resources. 386

387

### 388 Conclusion

In conclusion, this study compares demographic, clinical, laboratory, complications, and phenotype differences between COVID-19 waves I and II individuals with NCDs admitted to a district hospital with a high HIV/TB burden. Hypertension, diabetes, HIV/AIDS, obesity, CKD, CCF, COPD, and stroke were the most common comorbidity patterns. Except for HIV status, obesity, and previous stroke, all of them were similar between the two waves. In terms of clinical and laboratory findings, our study found that wave I had

statistically significant higher haemoglobin and HIV viral load. However, wave II had 395 statistically significant higher CXR abnormalities, FIO2, and uraemia. The average 396 survival time was longer in wave I, and the average length of stay of patients discharged 397 alive was shorter. The adjusted odds ratio for death vs discharge between waves I and II 398 was not statistically different. LCA revealed that the cardiovascular phenotype was the 399 most likely to die, followed by the diabetes and CKD phenotypes. Diabetes and 400 hypertension phenotypes had the lowest mortality rate. This study, conducted in a district 401 level hospital in South Africa, demonstrates the impact of COVID-19 in low-resource 402 settings. NCDs continue to play a significant role in the outcomes of COVID-19 patients. 403 Additional interventions are required in the treatment of COVID-19 associated with NCDs 404 because this association may cause elevated risk of complications and death among 405 patients attending care at the district hospital level. 406

### 407 **Abbreviations**

AIDS: acquired immunodeficiency syndrome; AKI: Acute kidney injury; ARDS: Acute 408 respiratory distress syndrome; ACE2: Angiotensin-Converting Enzyme 2; ART: 409 antiretroviral therapy; BMI: body mass index; COVID-19: CCF: congestive cardiac failure; 410 Coronavirus disease 2019; Cr: creatine; CRP: C-Reactive protein; COPD: Chronic 411 obstructive pulmonary disease; CXR: chest x-ray; CVDs: cardiovascular diseases; DIC: 412 Disseminated intravascular coagulation; FIO2: fraction of inspired oxygen; HAP: Hospital-413 acquired; pneumonia HIV: human immunodeficiency virus; HGT: hemo glucose test; ICU: 414 intensive care unit; IHD: ischemic heart disease; IL-6: Interleukin-6; IQR: interguartile 415 416 ranges; JHU: John Hopkin University; CHD: chronic heart disease; CKD: chronic kidney diseases; LCA: Latent Class Analysis; NCDs: non-communicable diseases; RT-PCR: 417

reverse transcriptase polymerase chain reaction SARS-CoV-2: severe acute respiratory

- syndrome coronavirus 2; SE: standard deviation; SPO2: Oxygen saturation; TB:
- 420 tuberculosis; TDF: Tenofovir disoproxil fumarate; TNF: tumor necrosis factor; WCC: white
- 421 cell count

## 422 **Declarations**

- 423 Contributions: Conception: ATM and PSN; Study design: ATM, PSN, DS, NE and JLT;
- Data collection: ATM, DS, NE, NS, and NB; Data analysis: AC; Writing and Editing:
- 425 ATM, DS, NE, NS, NB, NS, SG, AC, JLT, YT, MAD, RE, and PSN
- Ethics approval: Ethical approval for the study was obtained from the Stellenbosch
- 427 University health research ethics committee (Ethics reference number:
- 428 N20/05/020\_COVID-19).
- 429 Consent for publication: Not applicable.
- 430 Competing interests: The authors declare that they have no competing interests.
- 431 Funding: No funding was obtained for the study
- 432 Availability of data and materials: Data and materials for this study are provided as
- 433 supplementary information.
- 434

## 435 **References**

- 1. JHU. Coronavirus resources centre/Global Map, 2022.
- 437 https://coronavirus.jhu.edu/map.html

2. Statistics South Africa. South African Demographic and Health Survey 2016: Key 438 Indicator, 2016. https://dhsprogram.com/pubs/pdf/SR248/SR248.pdf 439 3. Statistics South Africa. Mid-year population estimates 2021, 440 https://www.statssa.gov.za/publications/P0302/P03022021.pdf 441 4. Moyo S, Ismail F, Van der Walt M, Ismail N, Mkhondo N, Dlamini S, Mthiyane T, 442 Chikovore J, Oladimeji O, Mametja D, Maribe P, Seocharan I, Ximiya P, Law I, 443 Tadolini M, Zuma K, Manda S, Sismanidis C, Pillay Y, Mvusi L. Prevalence of 444 bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a 445 multistage, cluster-based, cross-sectional survey. Lancet Infect Dis. 446 2022;22(8):1172-1180. 447 5. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, 448 pathophysiology, prognosis, and practical considerations. Diabetes Metab Syndr. 449 2020;14(4):303-310. 450 6. Western Cape Department of Health in collaboration with the National Institute 451 for Communicable Diseases, South Africa. Risk Factors for Coronavirus Disease 452 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape 453 454 Province, South Africa. Clin Infect Dis. 2021;73(7): e2005-e2015 7. Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, Murangandi P, 455 Savulescu D, Walaza S, Bam JL, Davies MA, Prozesky HW, Naude J, Mnguni 456 457 AT, Lawrence CA, Mathema HT, Zamparini J, Black J, Mehta R, Parker A, Chikobvu P, Dawood H, Muvhango N, Strydom R, Adelekan T, Mdlovu B, 458 Moodley N, Namavhandu EL, Rheeder P, Venturas J, Magula N, Blumberg L; 459 460 DATCOV author group. Risk factors for COVID-19-related in-hospital mortality in

- a high HIV and tuberculosis prevalence setting in South Africa: a cohort study.
  Lancet HIV. 2021;8(9): e554-e567
- 8. Docherty AB, Harrison EM, Green CA, Hardwick H, Pius R, Norman L, Holden
  KA, Read JM, Dondelinger F, Carson G, Merson L. Features of 16,749
- hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical
- 466 Characterisation Protocol,
- 467 2020.https://www.medrxiv.org/content/10.1101/2020.04.23.20076042v1
- 9. Jalili M, Payandemehr P, Saghaei A, Sari HN, Safikhani H, Kolivand P.
- 469 Characteristics and Mortality of Hospitalized Patients With COVID-19 in Iran: A
- 470 National Retrospective Cohort Study. Ann Intern Med. 2021;174(1):125-127
- 10. Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J. A
- systematic review of pathological findings in COVID-19: a pathophysiological
- timeline and possible mechanisms of disease progression. Mod Pathol.
- 474 **2020;33(11):2128-2138**.
- 11. Jassat W, Mudara C, Ozougwu L, Tempia S, Blumberg L, Davies MA, Pillay Y,
- 476 Carter T, Morewane R, Wolmarans M, von Gottberg A, Bhiman JN, Walaza S,
- 477 Cohen C; DATCOV author group. Difference in mortality among individuals
- admitted to hospital with COVID-19 during the first and second waves in South
- Africa: a cohort study. Lancet Glob Health. 2021;9(9): e1216-e1225.
- 12. Lalla U, Koegelenberg CFN, Allwood BW, Sigwadhi LN, Irusen EM, Zemlin AE,
- 481 Masha TE, Erasmus RT, Chapanduka ZC, Prozesky H, Taljaard J, Parker A,
- 482 Decloedt EH, Retief F, Jalavu TP, Ngah VD, Yalew A, Tamuzi JL, Baines N,
- 483 McAllister M, Zumla A, Nyasulu PS. Comparison of patients with severe COVID-

484	19 admitted to an intensive care unit in South Africa during the first and second
485	wave of the COVID-19 pandemic. Afr J Thorac Crit Care Med.
486	2021;27(4):10.7196/AJTCCM. 2021.v27i4.185.
487	13. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility, and impact of
488	SARSCoV-2 lineage B1.1.7 in England. medRxiv. 2020 doi: 10.1126/science.
489	abg3055.
490	14. Centers for Disease Control. SARS-CoV-2 Variant Classifications and
491	Definitions. 2021 https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-
492	info.html
493	15. Are EB, Colijn CB. Projected spread of COVID-19's second wave in South Africa
494	under different levels of lockdown 2021. doi: 10.1101/2021.01.22.21250308.
495	16. Naidoo S. The South African national health insurance: a revolution in health-
496	care delivery! J Public Health (Oxf). 2012;34(1):149-50.
497	17. Strategic Development Information and GIS Department. City of Cape Town -
498	2011 Census Suburb Khayelitsha, 2013.
499	http://www.capetown.gov.za/en/stats/2011CensusSuburbs/2011_Census_CT_Su
500	burb_Khayelitsha_Profile.pdf
501	18. Maylam P. The rise and decline of urban apartheid in South Africa. African
502	Affairs. 1990;89(354):57-84
503	19. Groenewald P, Bradshaw D, Daniels J, Zinyakatira N, Matzopoulos R, Bourne D,
504	Shaikh, N, Naledi, T. Surveillance de la mortalité au niveau local dans des pays
505	disposant de ressources limitées: Mise en lumière des disparités en matière de

- santé par une étude de cas menée dans la ville du Cap. Bulletin of the World
   Health Organization 2010, 88(6): 444–451.
- 20. Smit W, de Lannoy A, Dover RVH, Lambert E V, Levitt N, Watson V. Making
   unhealthy places: The built environment and non-communicable diseases in
   Khayelitsha, Cape Town. Health and Place 2016; 39: 196–203.
- 21. Lanza ST, Rhoades BL. Latent class analysis: an alternative perspective on
   subgroup analysis in prevention and treatment. Prev Sci. 2013;14(2):157-68.
- 513 22. Borgan, Ø. Aalen–Johansen Estimator. In Encyclopaedia of Biostatistics (eds P.
- Armitage and T. Colton), 2005. https://doi.org/10.1002/0470011815.b2a11001
- 23. United States Department of Health and Human Services Tenofovir disoproxil
- fumarate. April 27, 2020. https://aidsinfo.nih.gov/drugs/290/tenofovir-disoproxil fumarate/0/patient
- 518 24. United States Department of Health and Human Services Side effects of HIV
- medicines. Sept 24, 2020. https://hivinfo.nih.gov/understanding-hiv/fact-
- 520 sheets/hiv-medicines-and-side-effects
- 521 **25.** Honardoost M, Janani L, Aghili R, Emami Z, Khamseh ME. The Association
- 522 between Presence of Comorbidities and COVID-19 Severity: A Systematic
- 523 Review and Meta-Analysis. Cerebrovasc Dis. 2021;50(2):132-140.
- 26. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with
- severe coronavirus disease 2019 (COVID-19). Respir Med. 2020 Jun;
- 526 **167:105941**.

527	27. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease
528	2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020 Apr
529	30;130(4):304-309
530	28. De Miguel C, Rudemiller NP, Abais JM, Mattson DL. Inflammation and
531	hypertension: new understandings and potential therapeutic targets. Curr
532	Hypertens Rep. 2015;17(1):507.
533	29.Ran J, Song Y, Zhuang Z, Han L, Zhao S, Cao P, Geng Y, Xu L, Qin J, He D, Wu
534	F, Yang L. Blood pressure control and adverse outcomes of COVID-19 infection
535	in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 2020
536	;43(11):1267-1276.
537	30. Martínez-Rueda AJ, Álvarez RD, Méndez-Pérez RA, Fernández-Camargo DA,
538	Gaytan-Arocha JE, Berman-Parks N, Flores-Camargo A, Comunidad-Bonilla RA,
539	Mejia-Vilet JM, Arvizu-Hernandez M, Ramirez-Sandoval JC, Correa-Rotter R,
540	Vega-Vega O. Community- and Hospital-Acquired Acute Kidney Injury in COVID-
541	19: Different Phenotypes and Dismal Prognosis. Blood Purif. 2021;50(6):931-941
542	31. Fernandez C, Rysä J, Almgren P, Nilsson J, Engström G, Orho-Melander M,
543	Ruskoaho H, Melander O. Plasma levels of the proprotein convertase furin and
544	incidence of diabetes and mortality. J Intern Med. 2018;284(4):377-387.
545	32. Chiappetta S, Sharma AM, Bottino V, Stier C. COVID-19 and the role of chronic
546	inflammation in patients with obesity. Int J Obes (Lond). 2020;44(8):1790-1792.
547	33. Azar WS, Njeim R, Fares AH, Azar NS, Azar ST, El Sayed M, Eid AA. COVID-19
548	and diabetes mellitus: how one pandemic worsens the other. Rev Endocr Metab
549	Disord. 2020;21(4):451-463.

550	34. Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-Díaz ZM,
551	Salvador D Jr, Groothof D, Minder B, Kopp-Heim D, Hautz WE, Eisenga MF,
552	Franco OH, Glisic M, Muka T. Anemia, and iron metabolism in COVID-19: a
553	systematic review and meta-analysis. Eur J Epidemiol. 2020;35(8):763-773.
554	35. Balbi M, Caroli A, Corsi A, Milanese G, Surace A, Di Marco F, Novelli L, Silva M,
555	Lorini FL, Duca A, Cosentini R, Sverzellati N, Bonaffini PA, Sironi S. Chest X-ray
556	for predicting mortality and the need for ventilatory support in COVID-19 patients
557	presenting to the emergency department. Eur Radiol. 2021;31(4):1999-2012.
558	36. Brakohiapa EKK, Sarkodie BD, Botwe BO, Dzefi-Tettey K, Anim DA, Edzie EKM,
559	Goleku PN, Jimah BB, Amankwa AT. Comparing radiological presentations of
560	first and second strains of COVID-19 infections in a low-resource country.
561	Heliyon. 2021;7(8): e07818.
562	37. Au-Yong I, Higashi Y, Giannotti E, Fogarty A, Morling JR, Grainge M, Race A,
563	Juurlink I, Simmonds M, Briggs S, Cruikshank S, Hammond-Pears S, West J,
564	Crooks CJ, Card T. Chest Radiograph Scoring Alone or Combined with Other
565	Risk Scores for Predicting Outcomes in COVID-19. Radiology. 2022;302(2):460-
566	469
567	38. Firdose SR, Mattoo P, Malik AH, Viqar A. HRCT Chest in Patients Suffering from
568	COVID-19: Experience from a Tertiary Care Centre in India During Second Wave
569	of the Pandemic. Imaging, 2022.
570	https://doi.org/10.1556/1647.2022.00067

571	39. Moodley S, Sewchuran T. Chest radiography evaluation in patients admitted with
572	confirmed COVID-19 infection, in a resource limited South African isolation
573	hospital. SA J Radiol. 2022;26(1):2262.
574	40.Lin L, Wang X, Ren J, Sun Y, Yu R, Li K, Zheng L, Yang J. Risk factors and
575	prognosis for COVID-19-induced acute kidney injury: a meta-analysis. BMJ
576	Open. 2020;10(11): e042573.
577	41.Wang F, Ran L, Qian C, Hua J, Luo Z, Ding M, Zhang X, Guo W, Gao S, Gao W,
578	Li C, Liu Z, Li Q, Ronco C. Epidemiology and Outcomes of Acute Kidney Injury in
579	COVID-19 Patients with Acute Respiratory Distress Syndrome: A Multicenter
580	Retrospective Study. Blood Purif. 2021;50(4-5):499-505.
581	42. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang
582	B, Ding J, Li F. Detectable Serum Severe Acute Respiratory Syndrome
583	Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated with Drastically
584	Elevated Interleukin 6 Level in Critically III Patients with Coronavirus Disease
585	2019. Clin Infect Dis. 2020;71(8):1937-1942.
586	43. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X,
587	Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H,
588	Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of
589	patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
590	2020;395(10223):497-506.
591	44. Lin GL, McGinley JP, Drysdale SB, Pollard AJ. Epidemiology and Immune
592	Pathogenesis of Viral Sepsis. Front Immunol. 2018; 9:2147.

593	45. Li WX, Xu W, Huang CL, Fei L, Xie XD, Li Q, Chen L. Acute cardiac injury, and
594	acute kidney injury associated with severity and mortality in patients with COVID-
595	19. Eur Rev Med Pharmacol Sci. 2021;25(4):2114-2122
596	46. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from
597	2019-nCoV: host-directed therapies should be an option. Lancet.
598	2020;395(10224): e35-e36.
599	47. Moledina DG, Simonov M, Yamamoto Y, Alausa J, Arora T, Biswas A, Cantley
600	LG, Ghazi L, Greenberg JH, Hinchcliff M, Huang C, Mansour SG, Martin M,
601	Peixoto A, Schulz W, Subair L, Testani JM, Ugwuowo U, Young P, Wilson FP.
602	The Association of COVID-19 With Acute Kidney Injury Independent of Severity
603	of Illness: A Multicenter Cohort Study. Am J Kidney Dis. 2021;77(4):490-499.e1.
604	48. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for
605	extracorporeal therapies. Nat Rev Nephrol. 2020;16(6):308-310.
606	49. Liu D, Wang Q, Zhang H, Cui L, Shen F, Chen Y, Sun J, Gan L, Sun J, Wang J,
607	Zhang J, Cai Q, Deng J, Jiang J, Zeng L. Viral sepsis is a complication in
608	patients with Novel Corona Virus Disease (COVID-19). Med Drug Discov. 2020;
609	8:100057.
610	50. Popp M, Stegemann M, Riemer M, Metzendorf MI, Romero CS, Mikolajewska A,
611	Kranke P, Meybohm P, Skoetz N, Weibel S. Antibiotics for the treatment of
612	COVID-19. Cochrane Database Syst Rev. 2021;10(10):CD015025.
613	51. Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, Alexander P,
614	Ye Z, Lozano LEC, Munch MW, Perner A, Du B, Mbuagbaw L, Alhazzani W,
615	Pastores SM, Marshall J, Lamontagne F, Annane D, Meduri GU, Rochwerg B.

616	Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and
617	meta-analysis. Intensive Care Med. 2021;47(5):521-537.
618	52. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M,
619	Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B,
620	Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki
621	T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R,
622	Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J
623	Med. 2021;384(8):693-704.
624	53. Tamuzi JL, Ayele BT, Shumba CS, Adetokunboh OO, Uwimana-Nicol J, Haile
625	ZT, Inugu J, Nyasulu PS. Implications of COVID-19 in high burden countries for
626	HIV/TB: A systematic review of evidence. BMC Infect Dis. 2020;20(1):744.
627	54. Ospina-Tascón GA, Calderón-Tapia LE, García AF, Zarama V, Gómez-Álvarez
628	F, Álvarez-Saa T, Pardo-Otálvaro S, Bautista-Rincón DF, Vargas MP, Aldana-
629	Díaz JL, Marulanda Á, Gutiérrez A, Varón J, Gómez M, Ochoa ME, Escobar E,
630	Umaña M, Díez J, Tobón GJ, Albornoz LL, Celemín Flórez CA, Ruiz GO,
631	Cáceres EL, Reyes LF, Damiani LP, Cavalcanti AB; HiFLo-Covid Investigators.
632	Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on
633	Invasive Mechanical Ventilation and Clinical Recovery in Patients with Severe
634	COVID-19: A Randomized Clinical Trial. JAMA. 2021;326(21):2161-2171.
635	
636	
637	
< >	



Figure 1: Khayelitsha District in Cape Town/South Africa



Figure 2: Distribution of hospital admission by triage date



Figure 3: Fraction dead vs. time from triage, by wave



Figure 4: Comorbid patterns by latent disease class



Figure 5: Fraction dead vs time from triage, by latent class